Fatty liver, cardiometabolic disease and mortality.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
4
12
2019
medline:
17
6
2021
entrez:
3
12
2019
Statut:
ppublish
Résumé
We discuss the findings of the most recent metanalyses on the association between nonalcoholic fatty liver disease (NAFLD), cardiometabolic disease and mortality. Recent metanalyses have shown that NAFLD is associated with incident type 2 diabetes mellitus (T2DM) and incident cardiovascular disease (CVD). Nonalcoholic steatohepatitis, which can be diagnosed by liver biopsy only in tertiary care centers, is often associated with liver fibrosis, which has been shown by metanalyses to increase both cardiovascular and liver-related mortality. Hyperlipidemia, lipotoxicity and impaired insulin secretion are among the possible mechanisms underlying the association of NAFLD with T2DM and CVD. Metanalyses of the association between NAFLD and mortality in the general population, where risk stratification cannot be performed on the basis of liver biopsy, have given contradictory results. To establish conclusively whether NAFLD adds to known prognostic factors of death in the general population will require a shared operational definition of NAFLD, purposefully designed cohort studies, and the use of clinically relevant measures of effect size.
Identifiants
pubmed: 31789677
doi: 10.1097/MOL.0000000000000652
pii: 00041433-202002000-00006
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-31Références
Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. In press. https://www.jhep-reports.eu/article/S2589-5559(19)30079-5/fulltext.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol 2016; 64:1388–1402.
Kleiner DE, Brunt EM, Van Natta M, Behling C, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313–1321.
Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288:E462–E468.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73–84.
Liu Y, Zhong G-C, Tan H-Y, Hao F-B, et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep 2019; 9:11124.
Foschi FG, Bedogni G, Domenicali M, Giacomoni P, et al. Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterol 2018; 18:177.
Bedogni G, Bonino F, Tiribelli C. On the operational definition of fatty liver. Qeios 2018; 183https://www.qeios.com/read/article/183
Eslam M, Sanyal AJ, George J. Toward more accurate nomenclature for fatty liver diseases. Gastroenterology 2019; 157:590–593.
Bedogni G, De Matteis G, Fabrizi M, Alisi A, et al. Association of bright liver with the PNPLA3 I148 M gene variant in 1-year-old toddlers. J Clin Endocrinol Metab 2019; 104:2163–2170.
Gawrieh S, Wilson LA, Cummings OW, Clark JM, et al. the NASH Clinical Research Network. Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels. Am J Gastroenterol 2019; 114:1626–1635.
Rosso C, Mezzabotta L, Gaggini M, Salomone F, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology 2016; 63:107–116.
Dulai PS, Singh S, Patel J, Soni M, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017; 65:1557–1565.
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. New Engl J Med 2017; 377:2063–2072.
Rowe IA, Parker R. The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information. Nat Rev Gastroenterol Hepatol 2019; 16:449–450.
European Association for the Study of the Liver. EASL-ALEH Clinical Practice Guidelines: noninvasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63:237–264.
Pavlides M, Banerjee R, Sellwood J, Kelly CJ, et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 2016; 64:308–315.
Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018; 41:372–382.
Targher G, Byrne CD, Lonardo A, Zoppini G, et al. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65:589–600.
Ioannidis JP. Exposure-wide epidemiology: revisiting Bradford Hill. Stat Med 2016; 35:1749–1762.
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, et al. Nonalcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5:1544–1560.
Brouwers MCGJ, Simons N, Stehouwer CDA, Koek GH, et al. Relationship between nonalcoholic fatty liver disease susceptibility genes and coronary artery disease. Hepatol Commun 2019; 3:587–596.
Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 2017; 13:509–520.
Wu S, Wu F, Ding Y, et al. Association of nonalcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 2016; 6:33386.
Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men. Clin Gastroenterol Hepatol 2018; 16:1131.e5–1137.e5.
Ye Z-L, Guo W-Q, Li L. Sex-based differences in the association between nonalcoholic fatty liver disease and mortality. Clin Gastroenterol Hepatol 2019; 17:211–212.
Nonalcoholic fatty liver disease and mortality. Clin Gastroenterol Hepatol 2018; 16:1043.
Hernán MA. The hazards of hazard ratios. Epidemiology 2010; 21:13–15.
Sutradhar R, Austin PC. Relative rates not relative risks: addressing a widespread misinterpretation of hazard ratios. Ann Epidemiol 2018; 28:54–57. 10.1016/j.annepidem.2017.10.014.